Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
After finishing at $49.38 in the prior trading day, Veracyte Inc (NASDAQ: VCYT) closed at $47.71, down -3.38%. In other words, the price has decreased by -$3.38 from its previous closing price. On the day, 1.08 million shares were traded. VCYT stock price reached its highest trading level at $49.29 during the session, while it also had its lowest trading level at $47.67.
Ratios:
Our goal is to gain a better understanding of VCYT by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.29 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 38.40. For the most recent quarter (mrq), Quick Ratio is recorded 5.94 and its Current Ratio is at 6.23. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In the most recent recommendation for this company, Canaccord Genuity on October 20, 2025, initiated with a Hold rating and assigned the stock a target price of $40.
On March 20, 2025, Craig Hallum started tracking the stock assigning a Buy rating and target price of $45.
Goldman Downgraded its Buy to Neutral on December 05, 2024, whereas the target price for the stock was revised from $38 to $37.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 25 ’25 when Leite John sold 2,808 shares for $50.00 per share. The transaction valued at 140,400 led to the insider holds 86,291 shares of the business.
JONES EVAN/ FA sold 1,106 shares of VCYT for $55,576 on Nov 25 ’25. The Director now owns 29,362 shares after completing the transaction at $50.25 per share. On Nov 25 ’25, another insider, Evan Jones, who serves as the Director of the company, bought 5,000 shares for $49.38 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VCYT now has a Market Capitalization of 3771436032 and an Enterprise Value of 3445460992. As of this moment, Veracyte’s Price-to-Earnings (P/E) ratio for their current fiscal year is 125.65, and their Forward P/E ratio for the next fiscal year is 29.55. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.61. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.62 while its Price-to-Book (P/B) ratio in mrq is 3.00. Its current Enterprise Value per Revenue stands at 6.959 whereas that against EBITDA is 46.311.
Stock Price History:
The Beta on a monthly basis for VCYT is 1.78, which has changed by 0.11082649 over the last 52 weeks, in comparison to a change of 0.12934029 over the same period for the S&P500. Over the past 52 weeks, VCYT has reached a high of $50.71, while it has fallen to a 52-week low of $22.61. The 50-Day Moving Average of the stock is 27.33%, while the 200-Day Moving Average is calculated to be 50.74%.
Shares Statistics:
The stock has traded on average 983.23K shares per day over the past 3-months and 1140470 shares per day over the last 10 days, according to various share statistics. A total of 79.03M shares are outstanding, with a floating share count of 77.28M. Insiders hold about 2.26% of the company’s shares, while institutions hold 111.64% stake in the company. Shares short for VCYT as of 1763078400 were 5450021 with a Short Ratio of 5.54, compared to 1760486400 on 6722370. Therefore, it implies a Short% of Shares Outstanding of 5450021 and a Short% of Float of 7.6899999999999995.
Earnings Estimates
. The current assessment of Veracyte Inc (VCYT) involves the perspectives of 11.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $0.34, with high estimates of $0.44 and low estimates of $0.27.
Analysts are recommending an EPS of between $1.67 and $1.6 for the fiscal current year, implying an average EPS of $1.65. EPS for the following year is $1.6, with 11.0 analysts recommending between $2.08 and $1.21.
Revenue Estimates
11 analysts predict $131.73M in revenue for. The current quarter. It ranges from a high estimate of $133.2M to a low estimate of $130.6M. As of. The current estimate, Veracyte Inc’s year-ago sales were $118.63MFor the next quarter, 11 analysts are estimating revenue of $130.37M. There is a high estimate of $134.4M for the next quarter, whereas the lowest estimate is $124.1M.
A total of 12 analysts have provided revenue estimates for VCYT’s current fiscal year. The highest revenue estimate was $509.8M, while the lowest revenue estimate was $507.1M, resulting in an average revenue estimate of $508.32M. In the same quarter a year ago, actual revenue was $445.76MBased on 12 analysts’ estimates, the company’s revenue will be $565.62M in the next fiscal year. The high estimate is $577.7M and the low estimate is $553.48M.
